LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

LLY

1,053.95

+4.48%↑

JNJ

245.58

+1.27%↑

ABBV

229.45

+2.09%↑

NVS

164.49

+1.11%↑

MRK

123.71

+1.19%↑

Search

Microbot Medical Inc

Închisă

2.03 -5.14

Rezumat

Modificarea prețului

24h

Curent

Minim

1.99

Maxim

2.14

Indicatori cheie

By Trading Economics

Venit

-77K

-3.6M

Angajați

20

EBITDA

-79K

-3.6M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+264.08% upside

Dividende

By Dow Jones

Următoarele câștiguri

23 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

5.4M

146M

Deschiderea anterioară

7.17

Închiderea anterioară

2.03

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Microbot Medical Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23 feb. 2026, 22:36 UTC

Câștiguri

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23 feb. 2026, 22:32 UTC

Câștiguri

Woodside Energy Fiscal Year Net Profit Falls 24%

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23 feb. 2026, 23:58 UTC

Market Talk
Câștiguri

Global Energy Roundup: Market Talk

23 feb. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23 feb. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23 feb. 2026, 23:41 UTC

Achiziții, Fuziuni, Preluări

Crescent Capital Partners Owns 53% of ClearView Wealth

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23 feb. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23 feb. 2026, 23:40 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23 feb. 2026, 23:39 UTC

Achiziții, Fuziuni, Preluări

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23 feb. 2026, 23:31 UTC

Câștiguri

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23 feb. 2026, 23:28 UTC

Câștiguri

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23 feb. 2026, 23:27 UTC

Câștiguri

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23 feb. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23 feb. 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23 feb. 2026, 22:31 UTC

Câștiguri

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb. 2026, 22:24 UTC

Câștiguri

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy FY Underlying Ebitda A$700.9 Million

23 feb. 2026, 22:22 UTC

Câștiguri

Viva Energy Final Dividend 3.94 Australian Cents/Security

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23 feb. 2026, 22:21 UTC

Câștiguri

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23 feb. 2026, 22:20 UTC

Câștiguri

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Comparație

Modificare preț

Microbot Medical Inc Așteptări

Obiectiv de preț

By TipRanks

264.08% sus

Prognoză pe 12 luni

Medie 7.5 USD  264.08%

Maxim 12 USD

Minim 5 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMicrobot Medical Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.52 / 2.57Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Weak Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
help-icon Live chat